

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application once entered by the Examiner:

1-51. (Canceled).

52. (Currently Amended) A method for measuring protein S activity in a test plasma sample comprising:

(a) mixing a sample of test plasma with protein S deficient plasma,
at least one recombinant tissue factor selected from the group consisting of recombinant rabbit, recombinant porcine, recombinant equine and recombinant human tissue factors,
purified or synthetic phospholipids comprising phosphocholine, phosphoserine and phosphoethanolamine[.],

activated protein C,
calcium ion,
and measuring a clotting time of the sample,

(b) comparing the measurement in (a) to a standard curve derived from clotting times of plasma samples having a range of known protein S activities.

53. (Previously Presented) The method of claim 52 wherein the phospholipids comprise 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine.

54. (Previously Presented) The method of claim 53 wherein the molar ratio of 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine is about 3 to about 4 to about 5.

55. (Previously Presented) The method of claim 52 wherein the activated protein C has been activated by thrombin.

56. (Previously Presented) The method of claim 52 wherein the activated protein C has been activated by snake venom.

57. (Previously Presented) The method of claim 52 wherein the activated protein C comprises recombinant protein C.
58. (Previously Presented) The method of claim 52 wherein one or more of the protein S deficient plasma, recombinant tissue factor and activated protein C is derived from a mammalian source selected from the group consisting of a cow, a pig and a rabbit.
59. (Previously Presented) The method of claim 52 wherein one or more of the protein S deficient plasma, recombinant tissue factor and activated protein C is derived from a human.
60. (Previously Presented) The method of claim 52 wherein the measuring step is chromogenic.
61. (Currently Amended) The method of claim 52 wherein the measuring step is ~~spectrophotometries~~spectrophotometric.
62. (Previously Presented) The method of claim 52 wherein the at least one recombinant tissue factor comprises a recombinant rabbit tissue factor.
63. (Previously Presented) The method of claim 52 wherein the at least one recombinant tissue factor comprises a recombinant porcine tissue factor.
64. (Previously Presented) The method of claim 52 wherein the at least one recombinant tissue factor comprises a recombinant equine tissue factor.
65. (Previously Presented) The method of claim 52 wherein the at least one recombinant tissue factor comprises a recombinant human tissue factor.
66. (Previously Presented) The method of claim 52 wherein the at least one recombinant tissue factor is purified from mammalian cells.
67. (Previously Presented) A kit for measuring the functional activity of protein S in a plasma sample, said kit comprising one or more containers containing
protein S deficient plasma,
at least one recombinant tissue factor selected from the group consisting of recombinant rabbit, recombinant porcine, recombinant equine and recombinant human tissue factors,

purified or synthetic phospholipids comprising phosphocholine, phosphoserine and phosphoethanolamine,
calcium ion and
activated protein C.

68. (Previously Presented) The kit of claim 67 further comprising calibration plasma comprising about 100% percent protein S activity for preparing a standard curve.
69. (Previously Presented) The kit of claim 67 further comprising normal control plasma comprising between about 40-50% protein S activity.
70. (Previously Presented) The kit of claim 67 wherein the phospholipids comprise 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine.
71. (Currently Amended) The kit of claim ~~[[67]]~~70 wherein the molar ratio of 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine is about 3 to about 4 to about 5.
72. (Previously Presented) The kit of claim 67 wherein the at least one recombinant tissue factor comprises a recombinant rabbit tissue factor.
73. (Previously Presented) The kit of claim 67 wherein the at least one recombinant tissue factor comprises a recombinant porcine tissue factor.
74. (Previously Presented) The kit of claim 67 wherein the at least one recombinant tissue factor comprises a recombinant equine tissue factor.
75. (Previously Presented) The kit of claim 67 wherein the at least one recombinant tissue factor comprises a recombinant human tissue factor.
76. (Previously Presented) The kit of claim 67 wherein the at least one recombinant tissue factor is purified from mammalian cells.
77. (Previously Presented) The kit of claim 67 further comprising a chromogenic substrate.
78. (New) The kit of claim 67 wherein the activated protein C comprises recombinant protein C.